YS Biopharma (YS) Set to Announce Quarterly Earnings on Friday

YS Biopharma (NASDAQ:YS) will announce its earnings results before the market opens on Friday, April 19th.

YS Biopharma (NASDAQ:YS) last released its quarterly earnings data on Monday, January 22nd. The company reported ($0.16) earnings per share (EPS) for the quarter. The company had revenue of $13.64 million during the quarter. On average, analysts expect YS Biopharma to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

YS Biopharma Price Performance

YS stock opened at $0.94 on Thursday. YS Biopharma has a 12-month low of $0.35 and a 12-month high of $2.37. The company has a quick ratio of 1.09, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The stock’s 50 day simple moving average is $0.62 and its 200 day simple moving average is $0.57.

Hedge Funds Weigh In On YS Biopharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in YS. XTX Topco Ltd purchased a new stake in YS Biopharma during the 2nd quarter valued at $31,000. Barclays PLC purchased a new stake in YS Biopharma during the 2nd quarter valued at $150,000. Finally, FMR LLC purchased a new stake in shares of YS Biopharma in the 1st quarter worth $1,864,000. 52.64% of the stock is owned by institutional investors.

YS Biopharma Company Profile

YS Biopharma Co, Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001.